CAGR Value :
The global octreotide market was valued at USD 2.7 million in 2025 and is projected to reach USD 2.2 million by 2032, exhibiting a negative CAGR of -3.0% during the forecast period.
Report Studies :
Octreotide is an octapeptide that mimics natural somatostatin pharmacologically and is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone. It is usually in the form of a salt of acetic acid.
By Types :
Octreotide Injection
Octreotide Powder
Octreotide Microspheres
By Applications :
• Treating Acromegaly
• Treating Severe Diarrhea
• Others
Key Industry Players
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Chengdu Tiantaishan pharmaceutical
• Sinopharm A-Think Pharmaceuticals
• Sihuan Pharmaceutical Holdings Group Ltd.
• Shanghai Soho-Yiming Pharmaceuticals
• Yibin Pharmaceutical
• Crinos S.p.A. (part of Ipsen)
• Samarth Life Sciences Pvt. Ltd.
• Fresenius Kabi AG
• Jiangsu Hengrui Medicine Co., Ltd.
• Livzon Pharmaceutical Group Inc.
• Hybio Pharmaceutical Co., Ltd